PET imaging of endocannabinoid system
The endocannabinoid system consists of at least two G-protein coupled receptors (GPCRs), CB1R and CB2R, of endogenous agonists for these receptors (endocannabinoids, including anandamide and 2-arachidonoyl glycerol), and the enzymes for the synthesis and degradation of the endocannabinoids.
Endocannabinoids are produced from phospholipids, and secreted through extracellular membrane vesicles produced mainly by microglial cells in the brain, and by vascular endothelium, circulating macrophages and platelets. Anandamide (arachidonoyl ethanolamide, AEA) is degraded by fatty acid amide hydrolase 1 (FAAH). 2-arachidonoyl glycerol (2-AG) is produced by phospholipase C and diacylglycerol lipase (DAGL), and degraded mostly by monoacylglycerol lipase (MAGL). Endocannabinoids can also be oxidized by cyclooxygenase 2 (COX2). Intracellular Fatty acid binding proteins transport endocannabinoids to nuclear receptors and for enzymatic degradation.
CB1 receptors are abundant in the central and peripheral nervous system, also in the cerebellum, in glutamatergic and GABAergic pre- and postsynaptic terminals. Activation of presynaptic CB1Rs inhibits the neurotransmitter release, including glutamate. Low expression of CB1Rs is also seen in adipocytes and hepatocytes, gastrointestinal tract, and in the heart and skeletal muscle. Activation of CB1Rs promotes conservation of energy by increasing appetite and fat storage, and decreasing thermogenesis. PET imaging with [11C]OMAR has shown increased CB1R expression in the heart of obese humans and mice (Valenta et al., 2018). [18F]FMPEP-d2 imaging has shown upregulation of CB1Rs in acute activation of brown adipose tissue (Lahesmaa et al., 2018). Brain CB1R availability is reduced in cannabis and alcohol use disorders, and in chronic cigarette smokers (Hirvonen et al., 2018).
CB2 receptors are predominantly expressed on cells of the immune system, and found in the brain only in small quantities in neuronal, glial, and endothelial cells, but overexpressed in activated microglia and astrocytes. Some CB2R expression is also seen in the cardiac muscle, adipose tissue, spleen, and in the pancreas. CB2Rs in tonsils may be visible in brain imaging. During inflammation the CB2Rs are upregulated in immune system cells, and activation of CB2Rs by agonists dampens the inflammation. Platelets contain both CB1 and CB2 receptors.
Anandamide and N-arachidonoyl-dopamine (NADA), another endocannabinoid, are also ligands for TRPV1 (capsaicin receptor, vanilloid receptor 1), which has a diverse tissue distribution; it is found in the brain, in glial cells, liver, inflammatory cells, smooth muscles, bladder urothelium, and in keratinocytes of the epidermis. AEA activates TRPV1, leading to an increase in intracellular [Ca2+]. Additionally, TRPV1 may contribute to or regulate the uptake of AEA into endothelial cells.
Endocannabinoids and THC are lipophilic, and therefore bound to lipoproteins in the circulation. High lipophilicity also causes extensive binding to glassware and plastics (Garrett and Hunt, 1974). Transport of anandamide and fatty acids into and from erythrocytes is very fast, but the high plasma protein binding explains that only 10-20% of THC in blood resides in or on the surface of erythrocytes (Agurell et al., 1986). Plasma-to-blood ratios are about 1.5-1.7 for THC, 11-OH-THC, and THC-COOH when measured from fresh blood samples (Giroud et al., 2001; Schwope et al., 2011; Karschner et al., 2012); ratios from frozen blood samples may be markedly higher. Thus RBC-to-plasma ratio should be about 0.08-0.26.
Several PET tracers for CB1 receptors have been introduced, including [18F]FMPEP-d2, [18F]MK-9470, [11C]MePPEP, [11C]SD5024, and [11C]OMAR (also called [11C]JHU75528), and [18F]FPATPP. There may be marked sex difference in the uptake of the CB1R radioligands, which should be taken into account in design of studies (Laurikainen et al., 2019). Rodent in vitro autoradiography has shown that diet can affect CB1R density and distribution in the brain (Harrold et al., 2002). In rodent brain, [11C]MePPEP could not be displaced by endogenous cannabinoids (Terry et al., 2008), but changes in [18F]FMPEP-d2 binding may represent the level of endocannabinoid (Takkinen et al., 2018).
The CB2 receptors show less homology between species than CB1R. The existence of different isoforms of CB2R and their tissue and species specific expression patterns, and their intracellular activation (Brailoiu et al., 2014) may hinder the development of CB2R ligands for use in humans. Some PET tracers for CB2R have been developed, such as [11C]NE40, [11C]A-836339, [11C]KP23, [11C]RS-016 (Spinelli et al., 2018), and [18F]LU13 (Bündel et al., 2022), but currently those are only in preclinical use.
Fatty acid amide hydrolase (FAAH) degrades ethanolamides, including anandamide. Lysosomal enzyme NAAA (N-acylethanolamine-hydrolyzing acid amidase) catalyses the same reaction as FAAH. FAAH inhibitors have been studied for treatment of pain and addiction.
Several PET tracers have been introduced for quantification of the activity of FAAH enzyme, including [11C]CURB (Wilson et al., 2011; Rusjan et al., 2013 and 2018; Boileau et al., 2015b), [11C‑carbonyl]PF‑04457845 (Hicks et al., 2013), [18F]DOPP (Rotstein et al., 2014), [18F]FCHC (Shoup et al., 2015), [11C]MFTC (Kumata et al., 2015), and [11C]MK-3168 (Liu et al., 2013).
In humans, a single-nucleotide polymorphism in the FAAH gene, C385A (rs324420), encodes a threonine instead of conserved proline at amino-acid position 129 (P129T). This leads to reduced expression and functionality of the endocannabinoid inactivating enzyme FAAH and therefore higher endocannabinoid levels. Proline129 homozygotes have stronger placebo effects than C385A carriers. Approximately 38% of population of European descent have one or more copies of the variant form of the enzyme. This polymorphism may affect the results obtained with PET radiopharmaceuticals for FAAH, such as [11C]CURB, but it also provides a naturally occurring probe to examine the role of endocannabinoids in humans (Boileau et al., 2015a). In the brains of cannabis users, [11C]CURB binding is lower than in non-users (Boileau et al., 2016). In antisocial personality disorder (ASPD) amygdala [11C]CURB uptake is reduced, cerebellar and striatal FAAH expression is inversely related with impulsivity, and cerebellar FAAH is negatively associated with assaultive aggression (Kolla et al., 2021). Reduced FAAH is associated with higher D3R expression and [11C]-(+)-PHNO binding (Mansouri et al., 2020).
MAGL (monoacylglycerol lipase) is an important regulator of the endocannabinoid system in the central nervous system, where 2-AG is the main endocannabinoid, and MAGL is therefore a target for active drug development. MAGL inhibitors have been radiolabelled, and suitable tracers for in vivo PET imaging are being developed (Rempel et al., 2017; Arakawa et al., 2022).
[18F]T-401 binds MAGL reversibly and selectively in rodent, non-human primate, and human brains (Hattori et al., 2019; Takahata et al., 2022), and suitable for in vivo assessment of cerebral MAGL occupancy (Hattori et al., 2022; Takahata et al., 2022).
GPR55 is a G-protein coupled receptor which is sometimes described as the third cannabinoid receptor, although it lacks the cannabinoid binding pocket found in CB1 and CB2 receptors, and there is no consensus on whether endocannabinoids can actually activate GPR55 (Liu et al., 2015). Instead, L-α-lysophosphatidylinositol (LPI) may be the endogenous (non-cannabinoid) ligand of GPR55. GPR55 is expressed in the central nervous system and wide range of peripheral tissues, including pancreas, spleen, adrenals, bone, gastrointestinal tract, and adipose tissue (Liu et al., 2015). Some ligands aimed to bind to cannabinoid receptors may also bind to GPR55, or GPR18 and GPR119, the other "non-CB1/CB2 receptors".
Abood ME, Sorensen RG, Stella N (eds.): endoCANNABINOIDS - Actions at Non-CB1/CB2 Cannabinoid Receptors. Springer, 2013. doi: 10.1007/978-1-4614-4669-9.
Agurell S, Halldin M, Lindgren J-E, Ohlsson A, Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986; 38(1): 21-43. PMID: 3012605.
Almeida MM, Dias-Rocha CP, Calviño C, Trevenzoli IH. Lipid endocannabinoids in energy metabolism, stress and developmental programming. Mol Cell Endocrinol. 2022; 542: 111522. doi: 10.1016/j.mce.2021.111522.
Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997; 272(6): 3315-3323. doi: 10.1074/jbc.272.6.3315.
Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev. 2013; 65(2): 849-871. doi: 10.1124/pr.112.006387.
Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. J Cereb Blood Flow Metab. 2015a; 35(8): 1237-1240. doi: 10.1038/jcbfm.2015.119.
Boileau I, Rusjan PM, Williams B, Mansouri E, Mizrahi R, De Luca V, Johnson DS, Wilson AA, Houle S, Kish SJ, Tong J. Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [11C]CURB. J Cereb Blood Flow Metab. 2015b; 35(11): 1827-1835. doi: 10.1038/jcbfm.2015.133.
Bojesen IN, Hansen HS. Membrane transport of anandamide through resealed human red blood cell membranes. J Lipid Res. 2005; 46: 1652-1659. doi: 10.1194/jlr.M400498-JLR200.
Brailoiu GC, Deliu E, Marcu J, Hoffman NE, Console-Bram L, Zhao P, Madesh M, Abood ME, Brailoiu E. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry 2014; 53(30): 4990-4999. doi: 10.1021/bi500632a.
Burstein SH. The cannabinoid acids, analogs and endogenous counterparts. Bioorg Med Chem. 2014; 22(10): 2830-2843. doi: 10.1016/j.bmc.2014.03.038.
Chiurchiù V, Battistini L, Maccarrone M. Endocannabinoid signaling in innate and adaptive immunity. Immunology 2015; 144(3): 352-364. doi: 10.1111/imm.12441.
Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015; 16(1): 30-42. doi: 10.1038/nrn3876.
Di Marzo V, Wang J: The Endocannabinoidome - The World of Endocannabinoids and Related Mediators. Academic Press, 2015. eISBN: 9780128004296.
Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015; 290(14): 8711-8721. doi: 10.1074/jbc.M114.618447.
Fattore L (ed.) Cannabinoids in Neurologic and Mental Disease. Academic Press, 2015. eISBN: 9780124171244.
Gabrielli M, Battista N, Riganti L, Prada I, Antonucci F, Cantone L, Matteoli M, Maccarrone M, Verderio C. Active endocannabinoids are secreted on extracellular membrane vesicles. EMBO Rep. 2015; 16(2): 213-220. doi: 10.15252/embr.201439668.
Garrett ER, Hunt CA. Physicochemical properties, solubility, and protein binding of Δ9-tetrahydrocannabinol. J Pharm Sci. 1974; 63(7): 1056-1064. doi: 10.1002/jps.2600630705.
Gasperi V, Evangelista D, Savini I, Del Principe D, Avigliano L, Maccarrone M, Catani MV. Downstream effects of endocannabinoid on blood cells: implications for health and disease. Cell Mol Life Sci. 2015; 72(17): 3235-3252. doi: 10.1007/s00018-015-1924-0.
Hirvonen J. In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography. Clin Pharmacol Ther. 2015; 97(6): 565-567. doi: 10.1002/cpt.116.
Holland JP, Cumming P, Vasdev N. PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging 2013; 3(3): 194-216. PMID: 23638333.
Horti AG, Raymont V, Terry GE. PET imaging of endocannabinoid system. In: Dierckx RAJO et al. (eds.) PET and SPECT of Neurobiological Systems. Springer, 2014. doi: 10.1007/978-3-642-42014-6_11.
Khajehali E, Malone DT, Glass M, Sexton PM, Christopoulos A, Leach K. Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol. 2015; 88(2): 368-379. doi: 10.1124/mol.115.099192.
Kofalvi A (ed.): Cannabinoids and the Brain. Springer, 2008. doi: 10.1007/978-0-387-74349-3.
Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015; 36(5): 277-296. doi: 10.1016/j.tips.2015.02.008.
Normandin MD, Zheng M-Q, Lin K-S, Mason NS, Lin S-F, Ropchan J, Labaree D, Henry S, Williams WA, Carson RE, Neumeister A, Huang Y. Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab. 2015; 35: 1313-1322. doi: 10.1038/jcbfm.2015.46.
Pertwee RG (ed): Cannabinoids. Handbook of Experimental Pharmacology, 168, Springer, 2005. doi: 10.1007/b137831.
Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607): 3353-3363. doi: 10.1098/rstb.2011.0381.
Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, Kish SJ, Houle S, Tong J. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab. 2013; 33(3): 407-414. doi: 10.1038/jcbfm.2012.180.
Ueda N, Tsuboi K, Uyama T. Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J. 2013; 280(9): 1874-1894. doi: 10.1111/febs.12152.
Vemuri VK, Makriyannis A. Medicinal chemistry of cannabinoids. Clin Pharmacol Ther. 2015; 97(6): 553-558. doi: 10.1002/cpt.115.
Updated at: 2023-01-22
Created at: 2015-09-20
Written by: Vesa Oikonen